1) Why did Sigmund Freud use key elements in his theory ( psychoanalytic/psychodynamic) "sex and aggression-- what do they represent?

2) Using the neuroscience theory, explaining why people suffer from mental disorders

3) What kind of concerns would a cognitive psychologist deal with a client/patient. What are some of the significant influences would a cognitive psychologist be looking for?

4) How could you tell if someone favors the behavioral theory. What are some of the key elements

5) Which do you think is more important in development-- nature or nurture and why.

6) Why did the humanistic theory fall under the domain of free will. Why not determinism?

7) Which of the five theories (cognitive, behavioral, neurosciene, psychodynamic, and human) is closest to religious beliefs-- why?

8) Which Theory do you think is most important one. Please support your argument with an outside source.

Choose a Fortune 500 company that you are interested in researching for this

assignment.

This company should be a different company than your Week 5 Research Case Analysis

company or your Course Project company.

Write a report applying specific course concepts from this week's reading. Examples are

Competitive Intelligence, Demographics, Porter's 5 Forces, Value Chain Analysis, Resource-

Based View, Balanced Scorecard, Human Capital, and Social Capital.

The research case analysis may draw on items from the online environment—newspapers,

magazines, and websites—to provide current (i.e., within the last year) examples of course-

related topics (i.e., Business Strategy from this week's reading assignment). Relevance and

probable interest to the class are especially welcome.

The research case analysis should fully address the following points in this order.



The organization you have chosen,



Discuss the company utilizing specific course concepts from this week's assigned

Case Study: A major client asks one of its vendors to expand into India to lower the call center costs that they were incurring in Austin Texas. Austin was chosen because of the nature of the call – technology. India was chosen because of the labor pool with technology experience.

What are the issues the call center supplier has to deal with in considering whether to make this move and how to make it?

Case Study Continued: The same major client changes its mind after 6 months. This client was the 2nd largest company in the world at the time and they were a growing part of the vender’s business.

Because its initial mantra was flexibility (lease, equipment, human resources etc.), it was able to get out of its commitment, was paid to so by the client because they were so impressed with how low the costs were AND able to go to the next market in the same way.

•Adopt a Clear Product Strategy

•Test product in the target market

•    Make adjustments as needed

Jamison Day Consultants has been entrusted with the task of evaluating a business plan that has been divided into four sections—​marketing, ​finance, operations, and human resources.​ Chris, Steve,​ Juana, and Rebecca form the evaluation team. Each of them has expertise in a certain field and tends to finish that section faster. The estimated times taken by each team member for each section have been outlined in the table below. Further information states that each of these individuals is paid $90​/hour.                                                                       

​a) The optimal assignment of the function to a team member that minimizes the cost​ is:

Finance -----> Member ___________

Marketing ----> Member __________

Operations ------> Member __________

HR -----> Member ________

Considering the job description and job specification, what would you pay the incumbent of this position? What information would you consider to determine pay for this position?

Job Advertisment

The company is a medium accounting firm with 50 employees, located in Kamloops British Columbia

Daley & Company Chartered Professional Accountants is looking for an experienced Human Resources Manager to join our Kamloops office. The ideal candidate will have a proven track record of providing sound HR advice to employees and partners on day to day HR matters and have the ability to influence and drive HR strategy.

Main Responsibilities:

The Human Resources Manager will act as a trusted advisor to our employees and partners. Working closely with our Partners, you will be responsible for managing all aspects of the HR function to support the achievement of our business goals, including full-cycle recruitment, performance management, policy development, compensation, benefits, employee relations, coaching and training.

·        Act as the main point of contact for all HR support and manage the day to day HR operations for the firm;

·        Coach and counsel employees and partners on a broad range of matters and ensure consistent application in accordance with firm policies and procedures including: HR queries, legal issues, leadership, performance management issues, conflict management and disciplinary issues as required;

·        Responsible for full cycle recruitment, including development of job postings, advertising vacancies, screening resumes, coordinating and conducting interviews, reference checks and job offers;

·        Assist in the recruitment of CPA students, including liaising with colleges and universities, hosting information sessions or events, coordinating office tours, networking at various events, screening and interviewing candidates;

·        Develop a HR presence on social media and leverage social media in the recruitment process;

·        Conduct, and continue to develop our new hire orientation program;

·        Prepare HR correspondence including offer letters, new hire packages, letters of employment and salary letters;

·        Assist with staff requests regarding HR queries, issues, rules and regulations in accordance with firm policies and procedures;

·        Ensure that all HR forms, employee files, policies, manuals etc. are up-to-date;

·        Process documentation and prepare reports relating to personnel activities (staffing, recruitment, training, evaluations, professional and student development etc.);

·        Assist in organizing employee events;

·        Identify employment issues and recommend improvements, efficiencies and training opportunities;

·        Research, coordinate and manage training programs, HR projects and HR strategic initiatives as needed.

Qualifications, Skills & Personal Attributes

·        Previous HR experience in a Management or Generalist role;

·        Minimum 5 years of related HR work experience, preferably in a professional services firm;

·        CPHR designation an asset;

·        Maintains a high level of expertise on BC employment standards, common law decisions affecting employment and Human Rights and other areas of the law pertaining to employment;

·        Proven ability to influence and provide guidance on a broad range of employment matters at all levels in an organization;

·        Ability to handle confidential and sensitive information with tact and discretion;

·        Professional and personable manner with the ability to speak and present information to groups;

·        High degree of initiative with a proactive approach to work;

·        Strong organizational, multi-tasking skills and follow-through on commitments and deadlines;

·        Ability to work under pressure, adapt and respond to changing situations;

·        Excellent communication skills both written and verbal;

·        Excellent computer skills including MS Word, Excel, Outlook and various social media platforms with the ability to grasp new technological tools.

Nutrition

·       Which nutrients if deficient may cause Beriberi, Ariboflavinosis, Pellagra, and Scurvy? Which deficiency is also known as the “4 D’s” and what are the symptoms?       

·       Primary function of B vitamins (coenzymes)

·       Water soluble vitamins on which to focus:

§ Niacin (may also be derived from which specific amino acid?; which other B vitamin is necessary for this conversion?; also used as a supplement for high cholesterol)

§ B-6 (why is B-6 more likely to be toxic if overconsumed?)

§ B-12 (what is required for B-12 to be absorbed and where is it produced?; what is pernicious anemia and how is it treated?

§ Folate (what is the relationship to neural tube defects?; how can an anemia of folate deficiency be caused by B-12?)

·       What are the main functions of Vitamin C? What are signs/symptoms of a Vit C deficiency?

Chapter 11

·       Why are fat soluble vitamins more likely to cause toxicity and less likely to induce a deficiency than water soluble vitamins? Through which circulatory system do they travel?

·       Vit A (retinoid): 3 active forms; main function (vision); most common Vit A deficiency symptom? food sources of pre-formed vitamin A and provitamin A (beta-carotene)? What is the major effect of consuming large amounts of beta-carotene from food sources?

·       Vit D (calciferol); common sources (foods and sunlight); what two organs play a role in activating Vit D (by adding hydroxyl groups); main function (bone growth and maintenance); deficiency condition in children and adults

·       Vit E (tocopherol): main function (antioxidant)

·       Vit K: main function is in blood clotting; source of Vit K other than food (intestinal bacteria); why is a newborn given a dose of Vit K?

Neurotransmitters that open K+ channels in receiving cells are called

QUESTION 10

QUESTION 14

The adaptive immune system can target and kill specific pathogens because

QUESTION 17

What causes the signal that crosses a synapse to stop?

QUESTION 22

Which of the following hormonal signals could act as a ligand for a cytoplasmic receptor protein?

QUESTION 27

Which of the following might happen in individuals that had a nonsense mutation in the middle of the gene for growth hormone (GH) ?

Case Study 1
Quick Biotech
It is late in September 2010, and Michelle Chang, a doctoral student at the National
University of Singapore (NUS), is to meet her colleagues Henry Tan and Mike
Hammer from the Institute of Molecular Biology again in a few days to discuss the
course of action to be pursued for the establishment of Quick Biotech. Henry Tan
and Mike Hammer both hold doctorates in biology and work at NUS as senior
assistants. A few months before, they patented a process for the production of multi
protein complexes, which they had already put to successful use, and about which
they had received favourable feedback. Now, the three colleagues want to set-up a
company called Quick Biotech in order to apply the new technology to a wider field.
Background
The human body is exposed to numerous external influences and internal genetic
defects, which cause the proteins in our cells to malfunction. Proteins constitute the
basis of all biological processes. If proteins no longer fulfill their function adequately
owing to defects, this often results in life-threatening illnesses, such as cancer. This
is why almost all drugs have effect on proteins. Consequently, most research and
development work for drugs and therapies need protein, which is why both academic
research institutions and the pharmaceutical companies use proteins as a basis to
their research activities.
Recently, progress in fundamental research revealed the total of the proteins in a
cell, which in the case of human being amounts to more than 40,000 proteins. It
became obvious that the proteins in a cell do not work individually; rather, they
combine to act as protein complexes that are made up of numerous protein
components. In addition, virtually all biological processes in cells are executed by
such protein complexes. This has crucial consequences for research; in order to
understand how proteins work, protein machines must be explored as a whole, and
not only their individual protein components.
Nonetheless, academic institutes and the pharmaceutical industry have almost
exclusively focused on individual, isolated proteins. The primary reason for this was
that human protein machines are very difficult to produce in a pure form. Although
the development of modern, recombinant methods now enables the production of
individual protein components, there is still a demand for a technology that is able to
provide sufficient volumes of entire protein machine, which form the basis of
biological functions. This is also Michelle’s, Henry’s and Mike’s experience in their
research at NUS. They realize that no suitable technology for the production of
protein machines exists. This is why they developed their own technology: the
MultiBac technology.
The technology
The MultiBac technology uses a modified, yet greatly improved version of the so
called “baculovirus gene transfer vector” to produce any combination of proteins in
great volumes and of high quality. The genes of a great number of proteins, such as
human ones, can be placed on this gene transfer vector. This process can be carried
out in an ordinary molecular biology laboratory. The MultiBca gene transfer vector
multiplies in cell cultures and constitutes no danger to human beings. Therefore, no
special health and safety regulations are required to work with this system.
The gene transfer vector of the MultiBac system was developed to provide it with a
unique feature namely, that is particularly careful in the production of the desired
protein machines. For customers, this is a guarantee of the unsurpassed quality of
the protein complex produced with the MultiBac technology. In comparison with
conventional processes, the simplified MultiBac technology additionally saves a
substantial amount of time for the production of the desired protein product: it only
takes weeks rather than months. Also, the technology offers the possibility to build
numerous different protein complexes from the same protein components on a
modular basis and, thus, of supplying individual solution to customers’ problems.
Laboratories of renowned research institutes already use MultiBac, which NUS has
made available as trial specimens. This shows that the technology works, is mature
and has a selling potential. The process was patented last year by NUS, and since
then it was developed in the context of employment at the university. However, the
rights can be assigned to a start up, for instance, in the form of an exclusive license.
The next steps to launch the venture
In autumn 2010, Michelle is in the final stages of her doctoral thesis, which she
wants to complete by the year. After that, she needs to work full time for the new
company. In contrast, Henry and Mike want to retain their jobs at NUS and spend
less time on the company. As such, they would not be involved in the company’s
operative daily business but will assume an advisory function. They will receive
shares in the start-up but will not be on the company payroll.
One of the key roles of Henry and Mike will be to guarantee long term access to the
latest findings in scientific research. This model, whereby some of the founders
remain at the university, has already proved successful in a number of other
biotechnology start ups. Research in the field of biotechnology is very costly; both in
terms of time and money, so only by retaining close links with a research institution
will the company ensure that it will always work with the latest technologies and,
thus, remain competitive.
One of the greatest challenges currently perceived by the team is to secure funding
for the new company. Although the founders are able to invest S$200, 000 of their
personal savings into the enterprise and, thus, realize a small scale start up, present
plans are based on the assumption that at least S$500 000 of external capital will be
needed for the first two years.
These funds will primarily serve to finance Michelle’s position and a small team of lab
assistants in charge of producing the protein complex for the clients. The product will
be sold via a network of sales agents, and other functions, such as accounting and
finance, will be outsourced to a professional accountant.
Answer all questions.
1. Should Michelle consider debt or equity to finance QuickBiotech? Explain your
answer.

2. Would you consider any alternative sources or finance? Which one? Why?

3. Analyse other issues to be addressed before QuickBiotech is launched.

Please write all your answers in essay format. Do not answer in point-form unless
the questions mention “List” or “State”. It is not necessary to precede each answer
with an introduction and end with a summary. Proceed directly with the answer

Case Study 1
Quick Biotech
It is late in September 2010, and Michelle Chang, a doctoral student at the National
University of Singapore (NUS), is to meet her colleagues Henry Tan and Mike Hammer from the Institute of Molecular Biology again in a few days to discuss the course of action to be pursued for the establishment of Quick Biotech. Henry Tan and Mike Hammer both hold doctorates in biology and work at NUS as senior assistants. A few months before, they patented a process for the production of multi protein complexes, which they had already put to successful use, and about which they had received favourable feedback. Now, the three colleagues want to set-up a company called Quick Biotech in order to apply the new technology to a wider field.

Background
The human body is exposed to numerous external influences and internal genetic defects, which cause the proteins in our cells to malfunction. Proteins constitute the basis of all biological processes. If proteins no longer fulfill their function adequately owing to defects, this often results in life-threatening illnesses, such as cancer. This is why almost all drugs have effect on proteins. Consequently, most research and development work for drugs and therapies need protein, which is why both academic research institutions and the pharmaceutical companies use proteins as a basis to their research activities.

Recently, progress in fundamental research revealed the total of the proteins in a cell, which in the case of human being amounts to more than 40,000 proteins. It became obvious that the proteins in a cell do not work individually; rather, they combine to act as protein complexes that are made up of numerous protein components. In addition, virtually all biological processes in cells are executed by such protein complexes. This has crucial consequences for research; in order to understand how proteins work, protein machines must be explored as a whole, and not only their individual protein components.

Nonetheless, academic institutes and the pharmaceutical industry have almost exclusively focused on individual, isolated proteins. The primary reason for this was that human protein machines are very difficult to produce in a pure form. Although the development of modern, recombinant methods now enables the production of individual protein components, there is still a demand for a technology that is able to provide sufficient volumes of entire protein machine, which form the basis of biological functions. This is also Michelle’s, Henry’s and Mike’s experience in their research at NUS. They realize that no suitable technology for the production of protein machines exists. This is why they developed their own technology: the MultiBac technology.

The technology
The MultiBac technology uses a modified, yet greatly improved version of the so called “baculovirus gene transfer vector” to produce any combination of proteins in great volumes and of high quality. The genes of a great number of proteins, such as human ones, can be placed on this gene transfer vector. This process can be carried out in an ordinary molecular biology laboratory. The MultiBca gene transfer vector multiplies in cell cultures and constitutes no danger to human beings. Therefore, no special health and safety regulations are required to work with this system.

The gene transfer vector of the MultiBac system was developed to provide it with a unique feature namely, that is particularly careful in the production of the desired protein machines. For customers, this is a guarantee of the unsurpassed quality of the protein complex produced with the MultiBac technology. In comparison with conventional processes, the simplified MultiBac technology additionally saves a substantial amount of time for the production of the desired protein product: it only takes weeks rather than months. Also, the technology offers the possibility to build numerous different protein complexes from the same protein components on a modular basis and, thus, of supplying individual solution to customers’ problems.

Laboratories of renowned research institutes already use MultiBac, which NUS has made available as trial specimens. This shows that the technology works, is mature and has a selling potential. The process was patented last year by NUS, and since then it was developed in the context of employment at the university. However, the rights can be assigned to a start up, for instance, in the form of an exclusive license.

The next steps to launch the venture
In autumn 2010, Michelle is in the final stages of her doctoral thesis, which she wants to complete by the year. After that, she needs to work full time for the new company. In contrast, Henry and Mike want to retain their jobs at NUS and spend less time on the company. As such, they would not be involved in the company’s operative daily business but will assume an advisory function. They will receive shares in the start-up but will not be on the company payroll.
One of the key roles of Henry and Mike will be to guarantee long term access to the latest findings in scientific research. This model, whereby some of the founders remain at the university, has already proved successful in a number of other biotechnology start ups. Research in the field of biotechnology is very costly; both in terms of time and money, so only by retaining close links with a research institution will the company ensure that it will always work with the latest technologies and, thus, remain competitive.

One of the greatest challenges currently perceived by the team is to secure funding for the new company. Although the founders are able to invest S$200, 000 of their personal savings into the enterprise and, thus, realize a small scale start up, present plans are based on the assumption that at least S$500 000 of external capital will be needed for the first two years.

These funds will primarily serve to finance Michelle’s position and a small team of lab assistants in charge of producing the protein complex for the clients. The product will be sold via a network of sales agents, and other functions, such as accounting and finance, will be outsourced to a professional accountant.

Answer all questions.
1. Should Michelle consider debt or equity to finance QuickBiotech? Explain your answer.

2. Would you consider any alternative sources or finance? Which one? Why?

3. Analyse other issues to be addressed before QuickBiotech is launched.

Please write all your answers in essay format. Do not answer in point-form unless the questions mention “List” or “State”. It is not necessary to precede each answer with an introduction and end with a summary. Proceed directly with the answer

PLEASE GUYS NEED ANSWER IN ESSAY,THANK YOU